| 1 |
Wang M, Xu R, Huang J, Liao Q, Tang X, Shan Z, Zhong H, Rong X, Fu Y. Molecular characteristics of the full-length genome of occult hepatitis B virus from blood donors in China. Sci Rep 2022;12:8194. [PMID: 35581341 DOI: 10.1038/s41598-022-12288-0] [Reference Citation Analysis]
|
| 2 |
Meng F, Zhao J, Tan AT, Hu W, Wang SY, Jin J, Wu J, Li Y, Shi L, Fu JL, Yu S, Shen Y, Liu L, Luan J, Shi M, Xie Y, Zhou CB, Wong RW, Lu-En W, Koh S, Bertoletti A, Wang T, Zhang JY, Wang FS. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial. Hepatol Int 2021;15:1402-12. [PMID: 34850325 DOI: 10.1007/s12072-021-10250-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 3 |
Portilho MM, Bezerra CS, Mendonça ACDF, Marques VA, Nabuco LC, Villela-Nogueira CA, Ivantes CAP, Lewis-Ximenez LL, do Lago BV, Villar LM. Applicability of oral fluid samples for tracking hepatitis B virus mutations, genotyping, and phylogenetic analysis. Arch Virol 2021;166:2435-42. [PMID: 34146173 DOI: 10.1007/s00705-021-05122-x] [Reference Citation Analysis]
|
| 4 |
McNaughton AL, Revill PA, Littlejohn M, Matthews PC, Ansari MA. Analysis of genomic-length HBV sequences to determine genotype and subgenotype reference sequences. J Gen Virol 2020;101:271-83. [PMID: 32134374 DOI: 10.1099/jgv.0.001387] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 5 |
Huang BX, Liu Y, Fan ZP, Si LL, Chen RJ, Wang J, Luo D, Wang FS, Xu DP, Liu XG. Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations. World J Gastroenterol 2020; 26(35): 5314-5327 [PMID: 32994690 DOI: 10.3748/wjg.v26.i35.5314] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Chang XJ, Sun C, Chen Y, Li XD, Yu ZJ, Dong Z, Bai WL, Wang XD, Li ZQ, Chen D, Du WJ, Liao H, Jiang QY, Sun LJ, Li YY, Zhang CH, Xu DP, Chen YP, Li Q, Yang YP. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World J Gastroenterol 2019; 25(32): 4764-4778 [PMID: 31528100 DOI: 10.3748/wjg.v25.i32.4764] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 7 |
Menzo S, Minosse C, Vincenti D, Vincenzi L, Iacomi F, Zaccaro P, D'Offizi G, Capobianchi MR. Long-Term Follow-Up of Acute Hepatitis B: New Insights in Its Natural History and Implications for Antiviral Treatment. Genes (Basel) 2018;9:E293. [PMID: 29895748 DOI: 10.3390/genes9060293] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Zang H, Xu Z, Liu Y, Li X, Rong Y, Jiang L, You S, Hu J, Zhao J, Xu D, Xin S. Clinical and virological implications of A1846T and C1913A/G mutations of hepatitis B virus genome in severe liver diseases. Scand J Gastroenterol 2018;53:319-28. [PMID: 29322851 DOI: 10.1080/00365521.2018.1424934] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 9 |
Li P, Geng J, Li W, Xu X, Zhang X, Zheng W, Yu Y, Yang Z, Wang M. Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants. Virol J 2017;14:68. [PMID: 28376852 DOI: 10.1186/s12985-017-0739-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 10 |
Du X, Liu Y, Ma L, Lu J, Jin Y, Ren S, He Z, Chen X. Virological and serological features of acute hepatitis B in adults. Medicine (Baltimore) 2017;96:e6088. [PMID: 28207518 DOI: 10.1097/MD.0000000000006088] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 11 |
Geng Y, Wang X, Lu X, Wu X, Xu N, Han L, Xu J. Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy. Medicine (Baltimore) 2016;95:e2657. [PMID: 26844490 DOI: 10.1097/MD.0000000000002657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 12 |
Sarkar N, Pal A, Das D, Saha D, Biswas A, Bandopadhayay B, Chakraborti M, Ghosh M, Chakravarty R. Virological Characteristics of Acute Hepatitis B in Eastern India: Critical Differences with Chronic Infection. PLoS One 2015;10:e0141741. [PMID: 26571502 DOI: 10.1371/journal.pone.0141741] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 13 |
Araujo NM. Hepatitis B virus intergenotypic recombinants worldwide: an overview. Infect Genet Evol. 2015;36:500-510. [PMID: 26299884 DOI: 10.1016/j.meegid.2015.08.024] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 14 |
Li HM, Wang JQ, Wang R, Zhao Q, Li L, Zhang JP, Shen T. Hepatitis B virus genotypes and genome characteristics in China. World J Gastroenterol 2015; 21(21): 6684-6697 [PMID: 26074707 DOI: 10.3748/wjg.v21.i21.6684] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 15 |
Su F, Dai J, Yang S, Jiang X, Cui X, Ning H, Li J, Huang M. Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B. J Med Virol 2015;87:1527-31. [PMID: 26032700 DOI: 10.1002/jmv.24006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 16 |
Zeng DW, Dong J, Zhang JM, Zhu YY, Jiang JJ, Liu YR. HBeAg-negative chronic hepatitis patients should be monitored more strictly: a cross-sectional retrospective study on antiviral treatment-naïve patients. J Med Virol 2015;87:1682-8. [PMID: 25965250 DOI: 10.1002/jmv.24217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 17 |
Yu C, Gong X, Yang Q, Lian J, Xu K, Ruan B, Li L. The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B. Liver Int 2015;35:1549-56. [PMID: 25312687 DOI: 10.1111/liv.12701] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Chook JB, Teo WL, Ngeow YF, Tee KK, Ng KP, Mohamed R. Universal Primers for Detection and Sequencing of Hepatitis B Virus Genomes across Genotypes A to G. J Clin Microbiol 2015;53:1831-5. [PMID: 25788548 DOI: 10.1128/JCM.03449-14] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 19 |
Lee JH, Hong SP, Jang ES, Park SJ, Hwang SG, Kang SK, Jeong SH. Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B. J Med Virol. 2015;87:993-998. [PMID: 25712861 DOI: 10.1002/jmv.24148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 20 |
Soriano V, de Mendoza C, Peña JM, Barreiro P. Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. Expert Opin Pharmacother 2015;16:179-86. [PMID: 25529507 DOI: 10.1517/14656566.2015.973852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 21 |
Soriano V, de Mendoza C, Fernández-Montero JV, Labarga P, Barreiro P. Management and treatment of chronic hepatitis B in HIV-positive patients. Ann Med 2014;46:290-6. [PMID: 24716736 DOI: 10.3109/07853890.2014.899103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 22 |
Chen J, Yan L, Zhu FC, Liu JX, Li RC, Wang FZ, Li J, Zhuang H. Amino acid polymorphism in the reverse transcriptase region of hepatitis B virus and the relationship with nucleos(t)ide analogues treatment for preventing mother-to-infant transmission. J Med Virol. 2014;86:1288-1295. [PMID: 24777553 DOI: 10.1002/jmv.23948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 23 |
Soriano V, Mcmahon B. Strategic use of lamivudine in the management of chronic hepatitis B. Antiviral Research 2013;100:435-8. [DOI: 10.1016/j.antiviral.2013.08.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 24 |
Xu Z, Wu G, Li F, Bai J, Xing W, Zhang D, Zeng C. Positive selection signals of hepatitis B virus and their association with disease stages and viral genotypes. Infection, Genetics and Evolution 2013;19:176-87. [DOI: 10.1016/j.meegid.2013.07.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 25 |
Thibault V, Laperche S, Thiers V, Sayon S, Letort MJ, Delarocque-Astagneau E, Antona D. Molecular epidemiology and clinical characteristics of hepatitis B identified through the French mandatory notification system. PLoS One 2013;8:e75267. [PMID: 24086488 DOI: 10.1371/journal.pone.0075267] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 26 |
Soriano V, Poveda E, Vispo E, Barreiro P. Hepatitis B in HIV-infected patients. Clin Liver Dis 2013;17:489-501. [PMID: 23905818 DOI: 10.1016/j.cld.2013.05.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 27 |
Li X, Liu Y, Xu Z, Wan Z, Bai S, Mao P, Mao Y, Xin S, Xu D. A complete genomic analysis of hepatitis B virus isolated from 516 Chinese patients with different clinical manifestations. J Med Virol 2013;85:1698-704. [PMID: 23852705 DOI: 10.1002/jmv.23640] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 28 |
Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. J Infect. 2013;67:322-328. [PMID: 23796869 DOI: 10.1016/j.jinf.2013.06.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 29 |
Nishank SS. Endothelial Nitric Oxide Synthase (eNOS) Gene Polymorphism is Associated with Age Onset of Menarche in Sickle Cell Disease Females of India. Mediterr J Hematol Infect Dis 2013;5:e2013036. [PMID: 23795274 DOI: 10.4084/MJHID.2013.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 30 |
Gerada J, Borg E, Formosa D, Magro R, Pocock J. Tenofovir as rescue therapy following clinical failure to Lamivudine in severe acute hepatitis B. Mediterr J Hematol Infect Dis 2013;5:e2013035. [PMID: 23795273 DOI: 10.4084/MJHID.2013.035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 31 |
Baxa DM, Thekdi AD, Golembieski A, Krishnan PV, Sharif O, Kizy A, Shetron-Rama L, Jovanovich J, Chappell BJ, Snow-Lampart A, Borroto-Esoda K, Gordon SC. Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. J Hepatol 2013;58:212-6. [PMID: 23022497 DOI: 10.1016/j.jhep.2012.09.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 32 |
Morando F, Rosi S, Fasolato S, Cavallin M, Gola E, Gatta A, Angeli P. Severe acute hepatitis B in a treatment-naïve patient with antiviral drug resistant mutations in the polymerase gene. J Med Virol 2013;85:210-3. [DOI: 10.1002/jmv.23448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 33 |
Luo Q, Zhong Y, Yang Y, Xiong Q, Hu Z, Lu W, Huang P, Zhang N. Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains. J Med Virol 2012;84:1558-61. [DOI: 10.1002/jmv.23369] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 34 |
Ji D, Liu Y, Li L, Xu Z, Si LL, Dai JZ, Li X, Wang L, Yao Z, Xin SJ. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation. J Clin Virol. 2012;54:66-72. [PMID: 22398037 DOI: 10.1016/j.jcv.2012.02.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 35 |
Shi W, Carr MJ, Dunford L, Zhu C, Hall WW, Higgins DG. Identification of novel inter-genotypic recombinants of human hepatitis B viruses by large-scale phylogenetic analysis. Virology. 2012;427:51-59. [PMID: 22374235 DOI: 10.1016/j.virol.2012.01.030] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 36 |
Reis LM, Soares MA, França PH, Soares EA, Bonvicino CR. Clonal analysis of hepatitis B viruses among blood donors from Joinville, Brazil: Evidence of dual infections, intragenotype recombination and markers of risk for hepatocellular carcinoma. J Med Virol 2011;83:2103-12. [DOI: 10.1002/jmv.22246] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 37 |
Wu H, Chang C, Lin B, Yu F, Lin P, Hsu J, Yen C, Liao M, Shih W. Suppression of Hepatitis B Virus X Protein-Mediated Tumorigenic Effects by Ursolic Acid. J Agric Food Chem 2011;59:1713-22. [DOI: 10.1021/jf1045624] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 38 |
Li X, Wang L, Zhong Y, Wong VW, Xu Z, Liu Y, Li Q, Xin S, Zhao J, Xu D. Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients. J Clin Microbiol. 2010;48:4363-4369. [PMID: 20881176 DOI: 10.1128/jcm.01518-10] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
|
